Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Intralytix Receives FDA Regulatory Clearance and Expanded Use, Including in Ground Beef, for Phage-Based E. coli Food Safety Product
Intralytix, Inc. announced today that its broader acting and expanded use food safety product, EcoShield PX™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA) for elimination of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli (STEC) in many foods, including ground beef.
Intralytix Enters Into Joint Collaboration Agreement with the Eliava Foundation and Ferring Pharmaceuticals
Intralytix announces joint collaboration agreement to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health.
UPDATE: EcoActive™ Bacteriophage Therapy Enters Clinical Trial at the Mount Sinai Hospital
Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial.
Contest For The Best Cartoon Characters Of Bacteriophages
Intralytix is holding a contest for the creation of cartoon characters depicting bacteriophages.